FDA Panel to review Rexista NDA from Intellipharmaceutics

Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI) said FDA's Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management Advisory Committees will meet on July 26 to review an NDA for the company's Rexista oxycodone XR to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Its PDUFA date is Sept. 25...